If you ever suffered from depression or have been close to someone whose depression resists amelioration by available antidepressant treatments, you do appreciate the importance of the continuing efforts of academic and industrial research toward the development of new antidepressant drugs. As a result of the serendipitous finding in the 1950s that indicated antidepressant activity of iproniazid, a drug later found to act as a monoamine oxidase inhibitor, most of the currently prescribed antidepressants target neurons that utilize monoaminergic neurotransmitters. However, current antidepressant drugs have two main drawbacks: they take several weeks of treatment until their beneficial effects manifest and these treatments are not very effective acutely or following long-term administration in patients suffering from more chronic forms of depression. Based on the neuropharmacological mechanisms of current antidepressant drugs, their clinical utility is consistent with the traditional neurochemical conceptualization of depression, suggesting that the disorder is due to neurotransmitter imbalances. However, traditional hypotheses have recently been challenged based on converging evidence from studies in animals and humans that highlighted alterations in neuronal connectivity as underlying causes of mood disorders (Castren, 2005) .
